PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Clinical trial NCT03543813 · COMPLETED

Trial details

NCT number: NCT03543813
Sponsor: CytomX Therapeutics
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Solid Tumor, Adult Head and Neck Cancer Non Small Cell Lung Cancer Diffuse Large B Cell Lymphoma Esophageal Cancer

Start date: 2018-06-15
Primary completion: 2023-06-01
Enrollment: 133

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.